Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of cancers based on genetic abnormalities known as microsatellite instability or mismatch repair deficient mutations.
The final draft guidance published today marks the first time that NICE has made a decision on a cancer immunotherapy based on a 'basket trial', which enrols patients with tumours in different sites of the body but the same mutation signature, according to MSD.
